8-K current report · filed Nov 3, 2026

Spyre Therapeutics, Inc. (SYRE) 8-K Current Report: November 3, 2026

Item 2.02Item EX-99.1SYRE overview

Short answer

Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the quarter ended September 30, 2026 announced.

Spyre Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026 announced
  • Investor-relevant figures and management commentary contained in Exhibit 99.1
  • Results provide the latest view of Spyre’s cash position, operating expenses and clinical-development funding needs

Item EX-99.1 · Exhibit EX-99.1

  • SPY003 completed positive IBD monotherapy proof-of-concept, supporting progression toward potentially differentiated combination therapies
  • SKYLINE Part B enrolling ahead of schedule, with increased enrollment and three combination induction readouts expected Q3 2027
  • SPY072 showed RA activity but missed internal advancement standards, while PsA and axSpA failures ended rheumatic-disease development
  • HS strategy strengthened through SKYLIGHT initiation and planned pivotal SPY072 program, targeting a market forecast above $10 billion by 2035
  • Pro forma liquidity $1,467.9 million, including $378.0 million offering proceeds and $18.0 million ATM sales, supporting runway into second half 2029
  • Q3 net loss widened to $96.1 million from $11.2 million, with R&D expense rising to $89.2 million from $45.2 million

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Spyre Therapeutics, Inc. 8-K filings

Get the next SYRE 8-K as it lands

Follow SYRE for push alerts, or ask the research agent what this filing means.